- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2011
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 9,379
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, paclitaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Up to 120 Years · Female only
- Enrollment
- 571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate Liposome
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 128 more
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
- Interventions
- Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 100 Years
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Atrial Fibrillation
- Interventions
- Azimilide Dihydrochloride, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 79 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- pantoprazole
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 1 Day to 28 Days
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- TV-1106, Recombinant human growth hormone
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 23 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Procedure · Other · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 895
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more
- Conditions
- Pulmonary Embolism, Venous Thromboembolism
- Interventions
- Günther Tulip Vena Cava Filter
- Device
- Lead sponsor
- Cook Group Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 17
- States / cities
- Newark, Delaware • Washington D.C., District of Columbia • Miami, Florida + 13 more
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibroma
- Interventions
- Binimetinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, nab-paclitaxel, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 6
- States / cities
- Paducah, Kentucky • Portland, Oregon • Chattanooga, Tennessee + 1 more
- Conditions
- Vitreomacular Adhesion
- Interventions
- Not listed
- Lead sponsor
- Nova Southeastern University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 1,584 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sepulveda, California + 13 more
- Conditions
- Mitral Valve Insufficiency
- Interventions
- Twelve TMVR Implant, Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Other · Radiation
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, FDG-Positron Emission Tomography, Glofitamab, Ibrutinib, Magnetic Resonance Imaging, Obinutuzumab
- Procedure · Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- AP01
- Combination Product
- Lead sponsor
- Avalyn Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 24 more
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 58
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 37 more
- Conditions
- Active Polyarticular Juvenile Idiopathic Arthritis
- Interventions
- Abatacept
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more
- Conditions
- Advanced Prostate Cancer, Prostatic Neoplasms
- Interventions
- sipuleucel-T
- Biological
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 333
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 245 more
- Conditions
- Suicide and Self-harm
- Interventions
- HOME
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Hyperhidrosis
- Interventions
- glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%, glycopyrrolate, 4.0%, Vehicle
- Drug · Other
- Lead sponsor
- Journey Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 21
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • Encinitas, California + 17 more
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Interventions
- NN3201
- Drug
- Lead sponsor
- Novelty Nobility, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Belzutifan, Everolimus
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more